Search the Newsreel

PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR

This article announces a manager's transaction at QIAGEN N.V. involving Eva Pisa, a member of the administrative or supervisory body. The transaction is a retroactive adjustment for a February 2026 net share settlement, withholding an additional 544 shares to cover related taxes, and is …

Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip?

Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company's own outlook. For a …

Will FDA Clearance of QIAstat-Dx Bloodstream Panel Change Qiagen's (QGEN) Syndromic Testing Narrative?

Earlier this week, QIAGEN reported second-quarter 2026 results showing essentially flat year-on-year sales at US$535.04 million but higher net income of US$103.4 million, alongside shareholder-approved changes to its Articles that enable a reverse stock split and a capital repayment of up to US$200 million. …

Qiagen N.V. : DZ Bank reiterates its Buy rating

DZ Bank has reiterated its "Buy" rating for Qiagen N.V. Analyst Sven Kürten confirmed his positive recommendation for the biotechnology and medical research company. Qiagen N.V. is a global leader in providing chemical products for DNA and RNA manipulation.

Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing

Goldman Sachs Group Inc. has disclosed a 2.63% voting interest in Qiagen N.V., a Netherlands-based life sciences company, through a filing with the Dutch Authority for the Financial Markets. This stake is composed of both indirect real holdings and potential positions via various derivative …

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour FDA clearance marks QIAGEN's entry into U.S. bloodstream infection testing and establishes the first member of a planned QIAstat-Dx BCID panel …

Understanding Qiagen (QGEN) Reliance on International Revenue

Have you assessed how the international operations of Qiagen (QGEN) performed in the quarter ended June 2026? For this diagnostic products maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. …

Qiagen NV (QGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates

63,219 Shares in Qiagen N.V. $QGEN Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company recently acquired 63,219 shares of Qiagen N.V. (NYSE:QGEN) worth approximately $2.52 million. This purchase is part of broader institutional investment, with various firms like Boston Partners, Norges Bank, and Price T Rowe Associates also holding significant stakes, bringing total …

Qiagen N.V. (NYSE: QGEN) Q2 2026 profit, $496.7M synthetic buyback and cash flows

QIAGEN N.V. (NYSE: QGEN) reported Q2 2026 net sales of $535.04 million and net income of $103.401 million, with diluted EPS of $0.50. The company executed a $496.7 million synthetic share repurchase in January 2026, reducing outstanding shares by 5.0%, and approved a $0.35 …

Qiagen N.V. Stock 12‑Month Price Target Raised to $44.52, Implies 7% Upside

Qiagen N.V.'s average price target has been increased from $43.87 to $44.52 by 17 analysts, suggesting a 7% potential upside based on its closing price. The consensus rating remains a "Buy" from 22 covering analysts. Investors can explore more price target data and analyst …

Qiagen NV | 6-K: Report of foreign private issuer (related to financial reporting)

This article is a 6-K filing by Qiagen NV, which is a report for a foreign private issuer. These reports are typically related to financial reporting and other significant company updates that are required by regulatory bodies.

Quantinno Capital Management LP Has $5.30 Million Stock Holdings in Qiagen N.V. $QGEN

Quantinno Capital Management LP significantly reduced its stake in Qiagen N.V. by 40.6% in the first quarter, now holding 132,392 shares valued at approximately $5.3 million. Despite this, Qiagen's recent quarterly earnings exceeded expectations, with EPS of $0.62 and revenue of $535 million, and …

PTA-CMS: QIAGEN N.V.: Release of a capital market information

QIAGEN N.V. has filed its Form 6-K Report of Foreign Private Issuer for the quarterly period ended June 30, 2026, with the United States Securities and Exchange Commission (SEC). The document is now accessible on QIAGEN's website. This release provides important capital market information …

QIAGEN N.V. (NYSE: QGEN) tops Q2 EPS outlook and reaffirms 2026 targets

QIAGEN N.V. exceeded its Q2 2026 EPS outlook with adjusted diluted EPS of $0.62, against an outlook of at least $0.60 CER, and reaffirmed its full-year 2026 guidance for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 …

A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $45.5 to $46.09

This article provides a quick look at today's analyst ratings for Qiagen NV (QGEN.US), forecasting a target price between $45.50 and $46.09. It highlights the general sentiment and price targets from various financial institutions.

QIAGEN N.V. (NYSE: QGEN) sets $0.35 dividend and $200M buyback cap

QIAGEN N.V. (NYSE: QGEN) announced it will convene its 2026 Annual General Meeting on June 24, 2026. Shareholders will vote on a proposed cash dividend of $0.35 per ordinary share, totaling approximately $72 million, payable July 14, 2026. Additionally, the agenda includes authorizing a …

Qiagen (QGEN) Stock Faces An Execution Puzzle After Margin Rebound

Qiagen N.V. : Jefferies reiterates its Buy rating

Jefferies has reiterated its "Buy" rating for Qiagen N.V., reflecting a positive outlook on the stock. This comes as Qiagen's Q2 earnings exceeded expectations, though the company has maintained its guidance, similar to its peers. The article also provides a brief company profile, financial …

Qiagen NV (0RLT) Q4 2024 Earnings Report - Results, Call & Slides

Qiagen NV (0RLT) reported its Q4 2024 earnings, with an actual EPS of €0.56 matching the consensus but missing by less than €0.01 against expectations. The company's revenue for Q4 2024 was €452.34M, slightly beating the expected €452.21M. Qiagen also provided details for its …

Qiagen N.V. 2026 Q2 - Results - Earnings Call Presentation (NYSE:QGEN) 2026-08-06

QIAGEN NV : Deutsche Bank maintains a Buy rating

Deutsche Bank has reiterated its Buy rating for QIAGEN NV, with analyst Jan Koch maintaining a positive outlook on the stock. This comes amidst recent news that Jefferies also reiterated a Buy rating for QIAGEN and that the company's Q2 earnings were ahead of …

Qiagen (QGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, Qiagen (QGEN) reported revenue of $535.04 million, up 0.3% over the same period last year. EPS came in at $0.62, compared to $0.63 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $527.94 …

Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates

Qiagen (QGEN) exceeded Q2 earnings and revenue estimates, reporting $0.62 per share against a $0.60 consensus and revenues of $535.04 million, surpassing the $527.91 million estimate. Despite the beat, the company's shares have underperformed the S&P 500 year-to-date, and its Zacks Rank of #4 …

Earnings Flash (QGEN) QIAGEN N.V. Reports Q2 Revenue $535.0M, vs. FactSet Est of $527.5M

Earnings Flash (QGEN) QIAGEN N.V. Posts Q2 Adjusted EPS $0.62 per Share, vs. FactSet Est of $0.60

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Q2 2026 results: Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity …

Janus Henderson Group PLC Makes New Investment in Qiagen N.V. $QGEN

Janus Henderson Group PLC has made a new investment in Qiagen N.V., purchasing 366,661 shares valued at approximately $14.6 million, giving it a 0.18% stake. Other institutional investors have also adjusted their holdings, with institutional ownership of Qiagen reaching 70%. Analyst sentiment for Qiagen …

QIAGEN's growth pillars deliver 5% CER growth as U.S. testing falls

QIAGEN NV Revenue Breakdown – BIVA:QIA/N

QIAGEN NV (BIVA:QIA/N) generated 37.68 billion MXN in revenue last year. Its top-performing segment was Diagnostic Solutions, contributing 14.48 billion MXN. The United States was the largest regional contributor, accounting for 18.00 billion MXN of the total revenue.

Release according to Article 40, Section 1 of the WpHG

QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM. T. Rowe Price Group, Inc. reported a transaction on July 29, 2026, showing a capital interest and voting rights distribution of 4.97% in QIAGEN N.V. The company emphasizes it is …

Segall Bryant & Hamill LLC Lowers Holdings in Qiagen N.V. $QGEN

Segall Bryant & Hamill LLC reduced its stake in Qiagen N.V. by 24.5% in the first quarter, selling 36,110 shares but still retaining 111,177 shares worth approximately $4.45 million. Despite this reduction, other institutional investors like Groupe la Francaise, Janus Henderson Group PLC, Amundi, …

Qiagen NV expected to post earnings of 60 cents a share - Earnings Preview

Qiagen NV is projected to report earnings of 60 cents per share. This information comes from a Refinitiv earnings preview. The full article content is available on TradingView, which aggregates news from various sources including Reuters.